These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 31648470)

  • 1. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
    Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
    Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
    Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
    Front Med; 2019 Jun; 13(3):354-364. PubMed ID: 30680605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Yang L; Lai X; Yang T; Lu Y; Liu L; Shi J; Zhao Y; Wu Y; Chen Y; Yu J; Xiao H; Ouyang G; Ren J; Cao J; Hu Y; Tan Y; Ye Y; Cai Z; Xu W; Huang H; Luo Y
    Bone Marrow Transplant; 2024 Jan; 59(1):85-92. PubMed ID: 37907756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.
    Yan CH; Wang Y; Wang JZ; Chen YH; Chen Y; Wang FR; Sun YQ; Mo XD; Han W; Chen H; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2016 Sep; 9(1):87. PubMed ID: 27629395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor Lymphocyte Infusion for Relapsed Acute Leukemia or Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation: A Single-Institute Retrospective Analysis.
    Ogasawara M; Nozu R; Miki K; Sugimura S; Kojima K; Hidaka D; Ogasawara R; Okada K; Sugita J; Kobayashi N; Imamura M; Ota S
    Intern Med; 2024 Jan; 63(2):197-205. PubMed ID: 37225485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation.
    Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
    Front Med; 2019 Apr; 13(2):238-249. PubMed ID: 29656333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on the relapsd leukemia patients with graft versus host disease after allogeneic hematopoietic stem cell transplantation].
    Zhang XH; Fu HX; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Zhao T; Wang Y; Chen Y; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):323-7. PubMed ID: 21122312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
    Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients.
    Sun W; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Bone Marrow Transplant; 2019 Aug; 54(8):1198-1207. PubMed ID: 30518981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant.
    Hou MH; Lee CY; Ho CY; Yu TY; Hung GY; Huang FL; Chiou TJ; Liu CY; Yen HJ
    J Chin Med Assoc; 2023 Nov; 86(11):991-1000. PubMed ID: 37697465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.